Wedbush Forecasts Reduced Earnings for Compass Therapeutics

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Stock analysts at Wedbush lowered their FY2029 EPS estimates for shares of Compass Therapeutics in a report issued on Wednesday, November 5th. Wedbush analyst R. Driscoll now expects that the company will post earnings of $1.40 per share for the year, down from their prior estimate of $1.55. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06.

A number of other equities research analysts have also weighed in on CMPX. Guggenheim boosted their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Compass Point set a $10.00 price target on Compass Therapeutics in a research note on Monday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Lifesci Capital began coverage on Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Compass Therapeutics Price Performance

NASDAQ CMPX traded up $0.01 during trading on Friday, hitting $4.01. 687,629 shares of the company’s stock traded hands, compared to its average volume of 1,447,845. The stock has a fifty day moving average of $3.76 and a two-hundred day moving average of $2.96. Compass Therapeutics has a 12-month low of $1.27 and a 12-month high of $4.86. The firm has a market cap of $553.81 million, a P/E ratio of -8.90 and a beta of 1.48.

Institutional Trading of Compass Therapeutics

Several large investors have recently added to or reduced their stakes in CMPX. Creative Planning purchased a new position in Compass Therapeutics during the 2nd quarter valued at $30,000. Strs Ohio bought a new stake in shares of Compass Therapeutics during the 1st quarter valued at about $34,000. Apollon Wealth Management LLC purchased a new position in shares of Compass Therapeutics during the third quarter valued at about $35,000. Birchview Capital LP bought a new position in Compass Therapeutics in the first quarter worth about $46,000. Finally, Walleye Trading LLC purchased a new stake in Compass Therapeutics in the first quarter worth about $48,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.